Table 1.
Patient demographic and clinical characteristics
| Population #1 (n = 133) | Population #2 (n = 107) | |||||||
|---|---|---|---|---|---|---|---|---|
| IFX (n = 80) | ADA (n = 53) | Total (n = 133) | p value* | IFX (n = 60) | ADA (n = 47) | Total (n = 107) | p value* | |
| Gender, n (%) | ||||||||
| Female | 11 (13.8%) | 10 (18.9%) | 21 (15.8%) | 0.43 | 8 (13.3%) | 8 (17.0%) | 16 (15.0%) | 0.60 |
| Male | 69 (86.3%) | 43 (81.1%) | 112 (84.2%) | 52 (86.7%) | 39 (83.0%) | 91 (85.1%) | ||
| Age at the index date, years | ||||||||
| Mean (SD) | 33.9 (13.2) | 35.2 (12.9) | 34.4 (13.0) | 0.58 | 32.9 (12.6) | 33.7 (12.7) | 33.2 (12.6) | 0.76 |
| Median | 32.5 | 34 | 33 | 32 | 33 | 32 | ||
| Type of insurance, n (%) | ||||||||
| Family | 24 (30.0%) | 20 (37.7%) | 44 (33.1%) | 0.35 | 19 (31.7%) | 18 (38.3%) | 37 (34.6%) | 0.47 |
| Individual | 56 (70.0%) | 33 (62.3%) | 89 (66.9%) | 41 (68.3%) | 29 (61.7%) | 70 (65.4%) | ||
| Number of prescriptions of ADA or IFX after the index date (index date included) | ||||||||
| Mean (SD) | 10.3 (5.8) | 17.1 (12.5) | 13.0 (9.7) | 0.001 | 10.8 (5.3) | 18.5 (12.4) | 14.2 (9.9) | 0.001 |
| Median | 8 | 14 | 11 | 9 | 15 | 12 | ||
| Follow-up time after the index date, months | ||||||||
| Mean (SD) | 17.8 (9.5) | 19.2 (9.8) | 18.40 (9.6) | 0.41 | 17.9 (9.6) | 19.4 (9.7) | 18.6 (9.6) | 0.43 |
| Median | 17.5 | 18.1 | 18 | 16.9 | 18.6 | 18.1 | ||
| Surgery after the index date, n (%) | ||||||||
| 15 (18.8%) | 9 (17.0%) | 24 (18.1%) | 0.80 | 10 (16.7%) | 8 (17.0%) | 18 (16.8%) | 0.96 | |
| Immunostimulants after the index date, n (%) | ||||||||
| 0 | 1 (1.9%) | 1 (0.8%) | 0.40 | – | – | – | 0.96 | |
| Immunosuppressant prescription after the index date, n (%) | ||||||||
| 26 (32.5%) | 17 (32.1%) | 43 (32.3%) | 0.96 | 17 (28.3%) | 14 (29.8%) | 31 (29.0%) | 0.87 | |
| Enteral nutrition prescription after the index date, n (%) | ||||||||
| 53 (66.3%) | 38 (71.7%) | 91 (68.4%) | 0.51 | 40 (66.7%) | 35 (74.5%) | 75 (70.1%) | 0.38 | |
| Time between the first and second prescriptions, days | ||||||||
| Mean (SD) | 23.2 (25.8) | 14.3 (9.6) | 19.7 (21.3) | 0.02 | 16.6 (9.1) | 13.8 (7.7) | 15.4 (8.6) | 0.10 |
| Median | 14 | 14 | 14 | 14 | 14 | 14 | ||
| Time between the second and the third prescriptions, days | ||||||||
| Mean (SD) | 37.7 (24.4) | 22.4 (17.7) | 31.6 (23.1) | 0.0001 | 30.3 (7.4) | 21.7 (12.5) | 26.5 (10.8) | <0.0001 |
| Median | 28 | 15 | 28 | 28 | 16 | 28 | ||
| Average time between two successive prescriptions during maintenance phase, days | ||||||||
| Mean (SD) | – | – | – | – | 31.1 (14.4) | 27.5 (12.3) | 29.5 (13.6) | 0.18 |
| Median | – | – | – | – | 33.5 | 27 | 28.3 | |
| First dosea | ||||||||
| Mean (SD) | 3.3 (0.9) | 3.7 (0.9) | – | – | 3.2 (0.7) | 3.8 (0.8) | – | – |
| Median | 3 | 4 | – | – | 3 | 4 | – | |
| Second dosea | ||||||||
| Mean (SD) | 3.3 (1.0) | 2.5 (1.3) | – | – | 3.2 (0.7) | 2.6 (1.2) | – | – |
| Median | 3 | 2 | – | – | 3 | 2 | – | |
| Third dosea | ||||||||
| Mean (SD) | 3.2 (1.3) | 2.2 (1.5) | – | – | 3.2 (0.8) | 2.3 (1.4) | – | – |
| Median | 3 | 2 | – | – | 3 | 2 | – | |
| Average induction dosea | ||||||||
| Mean (SD) | 3.3 (1.0) | 3.1 (0.8) | – | – | 3.2 (0.7) | 3.2 (0.8) | – | – |
| Median | 3 | 3 | – | – | 3 | 3 | – | |
| Average maintenance dosea | ||||||||
| Mean (SD) | – | – | – | – | 2.3 (1.1) | 2.1 (0.9) | – | – |
| Median | – | – | – | – | 2 | 2 | – | |
ADA adalimumab, IFX infliximab, SD standard deviation
* Continuous variables were compared using the student test or the Wilcoxon test; categorical variables were compared using the Chi-square test or the Fisher’s exact test
aDose unit: for ADA, 1 dose = Injection 40 mg Syringe 0.8 mL and for IFX, 1 dose = I.V Infusion 100 mg